

Key highlights of data accepted by ASCO include:

Medicine	Abstract Title	Abstract Number/ Presentation Details
Kisqali® (ribociclib)*	Efficacy and safety of ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in NATALEE: Analysis across menopausal status and age	Abstract #516 Rapid Oral June 1, 8:00 – 9:30am CDT
Kisqali® (ribociclib)	Real-world (RW) analysis of characteristics and risk of recurrence (ROR) in Black patients (pts) with HR+/HER2– early breast cancer (EBC) eligible for NATALEE	Abstract #527 Poster Presentation June 2, 9:00am – 12:00pm CDT
Kisqali® (ribociclib)	Adjuvant WIDER: A phase 3b trial of ribociclib (RIB) + endocrine therapy (ET) as adjuvant treatment (tx) in a close-to-clinical-practice patient (pt) population with HR+/HER2– early breast cancer (EBC)	Abstract #TPS617 Poster Presentation June 2, 9:00am – 12:00pm CDT
Kisqali® (ribociclib)	First-line (1L) ribociclib (RIB) + endocrine therapy (ET) vs combination chemotherapy (combo CT) in clinically aggressive hormone receptor (HR)+/HER2– advanced breast cancer (ABC): A subgroup analysis of patients (pts) with or without liver metastases (mets) from RIGHT Choice	Abstract #1069 Poster Presentation June 2, 9:00am – 12:00pm CDT
Scemblix® (asciminib)	Efficacy and safety of asciminib (ASC) in patients (pts) with chronic-phase chronic myeloid leukemia (CML-CP) after 1 tyrosine kinase inhibitor (TKI): Interim analysis (IA) of the phase 2 ASC2ESCALATE trial	Abstract #6516 Rapid Oral May 30, 1:00 – 2:30pm CDT
Scemblix® (asciminib)	Primary endpoint results of the phase 3b ASC4START trial of asciminib (ASC) vs nilotinib (NIL) in newly diagnosed chronic phase chronic myeloid leukemia (CML-CP): Time to treatment discontinuation due to adverse events (TTDAE)	Abstract #6501 Oral Presentation June 2, 3:00 – 6:00pm CDT
Pluvicto® (lutetium Lu 177 vipivotide tetraxetan)	Clinical outcomes of prompt versus deferred 177Lu-PSMA-617 initiation for metastatic castration-resistant prostate cancer (mCRPC) based on prior androgen receptor pathway inhibitor (ARPI) and taxane chemotherapy exposure: a real-world PROstatE Cancer dISease observatIOn (PRECISION) data platform analysis	Abstract #e17030 Online Publication
Pluvicto® (lutetium Lu 177 vipivotide tetraxetan)	Real-world outcomes among patients with metastatic castration-resistant prostate cancer (mCRPC) receiving guideline-recommended therapies after treatment with 177Lu-PSMA-617: a real-world PROstatE Cancer dISease observatIOn (PRECISION) data platform analysis	Abstract #e17035 Online Publication
Pluvicto® (lutetium Lu 177 vipivotide tetraxetan)	PSMA-delay castration (DC): An open-label, multicenter, randomized phase 3 study of [177Lu]Lu-PSMA-617 versus observation in patients with metachronous PSMA-positive oligometastatic prostate cancer (OMPC)	Abstract #TPS5127 Poster Presentation June 2, 9:00am – 12:00pm CDT

Key highlights of data accepted by EHA include:

Medicine	Abstract Title	Abstract Number/ Presentation Details
Fabhalta® (iptacopan)	APPULSE-PNH: Oral iptacopan monotherapy demonstrates clinically meaningful hemoglobin (Hb) increases in patients (pts) with paroxysmal nocturnal hemoglobinuria (PNH) and Hb ≥10 g/dL on anti-C5 therapy	Abstract #S183 Oral Presentation June 13, 5:00 – 6:15pm CEST
Fabhalta® (iptacopan)	The 2-year safety and efficacy of iptacopan monotherapy in patients with paroxysmal nocturnal hemoglobinuria (PNH) from APPLY- and APPOINT-PNH studies who entered the roll-over extension program (REP)	Abstract #PF660 Poster Presentation June 13, 6:30 – 7:30pm CEST
Scemblix® (asciminib)	Asciminib (ASC) shows superior tolerability vs nilotinib (NIL) in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): Primary endpoint results of the phase (Ph) 3b ASC4START trial	Abstract #S166 Oral Presentation June 13, 5:00 – 6:25pm CEST
Scemblix® (asciminib)	Improved patient-reported outcomes (PROs) with asciminib (ASC) vs investigator-selected tyrosine kinase inhibitors (IS-TKIs) in newly diagnosed chronic myeloid leukemia (CML): ASC4FIRST wk 48 analysis	Abstract #PS1588 Poster Presentation June 14, 6:30 – 7:30pm CEST
Scemblix® (asciminib)	Interim analysis (IA) results from ASC2ESCALATE support asciminib (ASC) as a treatment (Tx) option in chronic-phase chronic myeloid leukemia (CML-CP) after 1 tyrosine kinase inhibitor (TKI)	Abstract #PF595 Poster Presentation June 13, 6:30 – 7:30pm CEST
Pelabresib (DAK539)	Pelabresib in combination with ruxolitinib for janus kinase inhibitor-naïve patients with myelofibrosis: 72-week follow-up with long-term efficacy outcomes of the phase III MANIFEST-2 study	Abstract #S223 Oral Presentation June 12, 5:00 – 6:15pm CEST
Ianalumab (VAY736)	A Phase 2 Study of Ianalumab in patients with primary immune thrombocytopenia previously treated with at least two lines of therapy (VAYHIT3)	Abstract #S312 Oral Presentation June 15, 11:00am – 12:15pm CEST
Rapcabtagene autoleucel (YTB323)	Rapcabtagene Autoleucel (YTB323) in patients with relapsed/refractory diffuse large B-cell lymphoma: A phase II trial clinical update	Abstract #PF1152 Poster Presentation June 13, 6:30 – 7:30pm CEST

Novartis in oncology

The Novartis oncology strategy focuses on people living with cancer and those who care for them, from loved ones to clinical care teams, including their providers. For the past 30+ years, the aim has been to extend and improve lives by discovering differentiated, innovative and practice-changing medicines for patients.